Production (Stage)
Caribou Biosciences, Inc.
CRBU
$1.12
$0.010.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -70.31% | -71.01% | -66.85% | 132.34% | 127.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.31% | -71.01% | -66.85% | 132.34% | 127.41% |
| Cost of Revenue | 10.14% | -13.65% | -7.82% | -1.00% | -6.42% |
| Gross Profit | -59.38% | -11.84% | -20.58% | 23.71% | 31.20% |
| SG&A Expenses | -14.81% | 10.65% | 12.12% | 21.78% | 18.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.43% | 13.93% | 19.72% | 29.07% | 25.12% |
| Operating Income | -20.99% | -39.17% | -47.15% | -16.91% | -12.24% |
| Income Before Tax | -28.51% | -46.37% | -56.56% | -10.90% | -6.24% |
| Income Tax Expenses | -104.66% | -104.66% | 175.71% | 175.71% | 175.71% |
| Earnings from Continuing Operations | -28.29% | -46.08% | -56.65% | -11.01% | -6.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.29% | -46.08% | -56.65% | -11.01% | -6.35% |
| EBIT | -20.99% | -39.17% | -47.15% | -16.91% | -12.24% |
| EBITDA | -21.01% | -40.04% | -48.44% | -15.77% | -10.93% |
| EPS Basic | -11.68% | -14.03% | -10.12% | 23.66% | 18.33% |
| Normalized Basic EPS | -7.96% | -10.32% | -6.73% | 23.78% | 18.34% |
| EPS Diluted | -11.68% | -14.03% | -10.12% | 23.66% | 18.33% |
| Normalized Diluted EPS | -7.96% | -10.32% | -6.73% | 23.78% | 18.34% |
| Average Basic Shares Outstanding | 12.91% | 22.54% | 34.09% | 43.91% | 32.44% |
| Average Diluted Shares Outstanding | 12.91% | 22.54% | 34.09% | 43.91% | 32.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |